Nuvectis Pharma, INC Form 4 insider transactions

Michael J. Carson, Vice President, Finance of Nuvectis Pharma, Inc., received 30,000 shares of common stock on August 3, 2026.

Marlio Charles Mosseri, a director at Nuvectis Pharma, Inc., reported the acquisition of 50,000 common shares.

Nuvectis Pharma CEO Ron Bentsur acquired 12,500 shares of common stock for $250,000 in a public offering on June 30, 2026.

Director Kenneth Hoberman acquired 35,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Director James F. Oliviero III was granted 35,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Director Juan Sanchez acquired 35,000 shares of restricted common stock in Nuvectis Pharma, Inc. as part of a compensation grant.

Director Matthew L. Kaplan was granted 35,000 shares of restricted common stock in Nuvectis Pharma, Inc.

Nuvectis Pharma's Chief Development & Operations Officer, Shay Shemesh, was granted 150,000 restricted common shares vesting over three years.

Nuvectis Pharma's Chairman and CEO, Ron Bentsur, acquired 150,000 shares of restricted common stock, increasing his beneficial ownership.

Nuvectis Pharma's Chief Science & Business Officer, Enrique Poradosu, was granted 150,000 shares of restricted common stock, vesting over three years.

Michael J. Carson, Nuvectis Pharma's Vice President of Finance, was granted 61,200 shares of restricted common stock.

Nuvectis Pharma's Chairman and CEO, Ron Bentsur, acquired 5,000 shares of common stock at $5.72 per share.

Nuvectis Pharma Director Juan Sanchez acquired 13,000 shares of common stock at a weighted average price of $5.79 per share.

Nuvectis Pharma Director Matthew L. Kaplan purchased 11,000 shares of common stock at a weighted average price of $5.84.

Nuvectis Pharma, Inc. Director Juan Sanchez was granted 30,000 shares of common stock, vesting over three years.

Marlio Charles Mosseri, a director and 10% owner of Nuvectis Pharma, increased his indirect beneficial ownership of common stock through recent purchases totaling 154,770 shares.

Charles Mosseri Marlio, a Director and 10% owner of Nuvectis Pharma, Inc., acquired 5,603 shares of common stock indirectly through Emerald Hill Ventures SARL SPF at $7.99 per share.

Marlio Charles Mosseri, a Director and 10% owner of Nuvectis Pharma, Inc., has significantly increased his beneficial ownership through recent open market purchases of common stock.

Nuvectis Pharma, Inc. Director Kenneth Hoberman was granted 30,000 shares of restricted common stock, increasing his total beneficial ownership to 133,140 shares, with vesting tied to continued board service.

Nuvectis Pharma, Inc. Director Matthew L. Kaplan was granted 30,000 shares of restricted common stock, vesting over three years, as part of his compensation.

Nuvectis Pharma, Inc. Director James F. Oliviero III was granted 30,000 shares of restricted common stock, vesting over three years, increasing his direct beneficial ownership to 87,828 shares.

Director Charles Mosseri Marlio reports purchasing 21,167 shares of Nuvectis Pharma at an average price of $8.11.

Charles Mosseri Marlio, a director of Nuvectis Pharma, Inc., amended a previous SEC filing to correct the prices of common stock acquired and include transactions from May 9, 2025.

Charles Mosseri Marlio, a director of Nuvectis Pharma, indirectly increased his holdings through purchases made by Emerald Hill Ventures SARL SPF between May 6th and May 8th, 2025.

Director Charles Mosseri Marlio reports purchasing 240,000 shares of Nuvectis Pharma at $5 per share, increasing his indirect holdings.

Shay Shemesh, Chief Development & Operations Officer of Nuvectis Pharma, reports acquiring 150,000 shares of restricted common stock on January 2, 2025.

Enrique Poradosu, Chief Science & Business Officer of Nuvectis Pharma, Inc., reports the acquisition of 150,000 shares of restricted common stock.

Michael J. Carson, VP of Finance at Nuvectis Pharma, reports the acquisition of 51,000 shares of restricted common stock on January 2, 2025.

Ron Bentsur, Chairman and CEO of Nuvectis Pharma, reports the acquisition of 250,000 shares of restricted common stock on January 2, 2025.

Ron Bentsur, Chairman and CEO of Nuvectis Pharma, recently purchased 4,500 shares of common stock at an average price of $4.65.